Last updated: July 2, 2026
Executive summary: No supplier map can be produced for INCASSIA without the drug’s active ingredient and FDA application identifier. “INCASSIA” is not sufficient to determine NDA/BLA, dosage form(s), listed manufacturers on the label and FDA Drugs@FDA, contract manufacturing and packaging networks (CMO/CDMO), or Orange Book–listed manufacturing sites.
What is INCASSIA’s active ingredient and FDA identifier (NDA/BLA) that determines its supply chain?
Featured snippet answer: Supplier assignments in pharma come from label “Manufactured for/By” and from FDA records tied to the drug’s NDA/BLA and dosage form strength. Without those identifiers, supplier selection cannot be made.
How the INCASSIA name maps to the supply chain records
- FDA label “Manufactured for” and “Manufactured by” lines
- Drugs@FDA application record for the marketed product
- Orange Book record for listed patents tied to that NDA
- FDA facility listings (establishment registration and drug listing) that anchor CMO/CDMO use
Which companies supply INCASSIA as contract manufacturer, packager, or labeler?
Featured snippet answer: The only defensible “suppliers” list is the set of named entities on the FDA label and application record for the exact INCASSIA dosage form and strength.
Typical supplier categories to capture from FDA labeling
- Drug substance (API) supplier or API manufacturer
- Drug product (DP) manufacturer (fill-finish or tablet/capsule manufacture)
- Secondary packaging supplier (bottling, blister packing)
- Labeler/distributor (often the marketing authorization holder)
- Logistics and cold-chain (if applicable)
What this requires in practice
- “Manufactured for” entity on the package insert
- “Manufactured by” and address on the label
- Site names corresponding to the dosage form in the approved NDA
What does the INCASSIA label say about “manufactured for/by” entities?
Featured snippet answer: Supplier names are taken directly from the commercial product label and the corresponding FDA submission for INCASSIA.
Label line items that usually identify suppliers
- Manufacturer name and facility address
- Strength-specific manufacturing notes
- Packaging format (bottle vs blister vs unit-dose)
- Sponsor/marketing authorization holder
Are INCASSIA suppliers different across dosage forms or strengths?
Featured snippet answer: Yes. Manufacturing and packaging tend to vary by dosage form and strength, even within the same NDA, and FDA label lines often differ by configuration.
Common patterns
- Same API, different DP CMOs for different strengths
- Same DP CMO, different packaging contractors for blister vs bottle
- Alternate fill-finish sites added via manufacturing supplements
How can INCASSIA supply risk change based on manufacturing sites and approvals?
Featured snippet answer: Supply risk is site-specific and tied to FDA facility status and regulatory history for each manufacturing establishment.
Risk factors typically surfaced by FDA facility and compliance records
- Inspection outcomes for DP and fill-finish sites
- Process changes and manufacturing supplement filings
- Product holds or recalls linked to specific lots and sites
How to identify the real CMO/CDMO behind INCASSIA manufacturing?
Featured snippet answer: Track the entity names across three layers: FDA label, manufacturing section in the NDA record, and facility registration tied to the site address.
Evidence chain used in supplier diligence
- Label “Manufactured by/for” entities
- Facility site address alignment to FDA establishment registration
- Consistency across supplements and post-approval manufacturing changes
Does INCASSIA have multiple suppliers listed for API or DP?
Featured snippet answer: Multiple suppliers are common, but the list must be extracted per NDA/dosage form from label and FDA records.
Where multiple suppliers typically appear
- API named-manufacturer and alternative sources in filings
- DP manufacturing site alternates in supplements
- Contract packaging alternates for different package sizes
What supply-chain transparency exists through FDA databases for INCASSIA?
Featured snippet answer: Transparency exists at the level of labeled manufacturers and registered establishments, not necessarily at the level of all upstream raw material suppliers.
FDA resources used for supplier mapping
- Drugs@FDA (application record, label PDFs, approval history)
- Orange Book (NDA-level linkage)
- FDA establishment registration and drug listing (site registration)
- Enforcement reports (if relevant)
Key Takeaways
- A reliable supplier list for INCASSIA requires the active ingredient and the FDA NDA/BLA tied to the exact dosage form and strength.
- “INCASSIA” alone is not enough to extract labeled “manufactured for/by” entities, FDA application-linked manufacturers, or CMO/CDMO sites.
- Supplier diligence should use the label and FDA records for the specific product configuration; otherwise, supplier identifications risk mixing different products or strengths.
FAQs
-
What determines who the “supplier” of a drug is in pharma records?
The named entities in the FDA-approved label and NDA/BLA-linked manufacturing information for the exact dosage form and strength.
-
How do you identify the contract manufacturer for a marketed drug?
By mapping label “Manufactured by/for” entities to FDA facility registration tied to the specific site address and dosage form.
-
Do API and drug product suppliers always come from the same company?
No. Many drugs use separate API manufacturers and DP CMOs, with packaging contractors differing by package format.
-
Can a drug have different suppliers for different strengths?
Yes. Manufacturing and packaging can differ by strength even within the same marketing authorization.
-
Where do investors and legal teams find supplier and manufacturing site evidence?
FDA label documents, Drugs@FDA records, and FDA establishment registration tied to the labeled manufacturer sites.
References
No sources cited because INCASSIA’s active ingredient and FDA application identifier were not provided, and no accurate supplier mapping can be generated from the available information.
